Polku Therapeutics Named VC Favorite at Health Design Pitch Competition

Helsinki, Finland – October 16, 2024 – Polku Therapeutics has been named the VC Favorite at the Health Design Pitch Competition, a prestigious event showcasing the most innovative life science companies shaping the future of healthcare.

The competition brings together venture capitalists, industry experts, and early-stage companies to identify transformative solutions addressing critical healthcare challenges.

The award recognizes Polku Therapeutics' progress in developing disease-modifying therapies for neurodegenerative disorders, addressing one of the largest unmet medical needs of our time. The company's approach focuses on two key protein targets — prolyl oligopeptidase (PREP) and protein phosphatase 2A (PP2A) — positioning it at the forefront of therapeutic innovation for Parkinson's disease, Alzheimer's disease, and tauopathies.

The competition provided Polku Therapeutics with the opportunity to present its scientific advancements and therapeutic pipeline to leading investors and industry stakeholders. The VC Favorite designation underscores the company's potential to make a meaningful impact on treatment options for patients affected by these devastating conditions.

About Polku Therapeutics

Polku Therapeutics is a Helsinki-based biotechnology company developing novel therapeutics for neurodegenerative diseases.